LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

B.C. Cho; M-J. Ahn; J.H. Kang; R. Soo; T.R. Baisamut; J.C-H. Yang; I. Cicin; Dongwook Kim; Yi‐Long Wu; Shaowen Lu; K. Lee; Y-K. Pang; A. Zimina; C.H. Fong; E. Poddubskaya; Y. Kim; T. An; H. Lee; Hyun Jeoung Byun; B. Zaric

doi:10.1016/j.annonc.2022.10.349

LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

B.C. Cho(Yonsei University), M-J. Ahn(Samsung Medical Center), J.H. Kang(The Catholic University of Korea Seoul St. Mary's Hospital), R. Soo(National University Cancer Institute, Singapore), T.R. Baisamut(Mahidol University), J.C-H. Yang(National Taiwan University), I. Cicin(Trakya University), Dongwook Kim(Seoul National University Hospital), Yi‐Long Wu(Guangdong Provincial People's Hospital), Shaowen Lu(Shanghai Jiao Tong University), K. Lee(Chungbuk National University Hospital), Y-K. Pang(University of Malaya), A. Zimina(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), C.H. Fong(Hospital Pulau Pinang), E. Poddubskaya(Sechenov University), Y. Kim(Yuhan University), T. An(Yuhan University), H. Lee(Yuhan University), Hyun Jeoung Byun(Yuhan University), B. Zaric(Institute for Pulmonary Diseases of Vojvodina)

Annals of Oncology

November 1, 2022

10.1016/j.annonc.2022.10.349

Cited by 8Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis